27576608|t|Ocular toxicity of AUY922 in pigmented and albino rats
27576608|a|AUY922, a heat shock protein 90 inhibitor is associated with ocular adverse events (AEs). To provide a better understanding of ocular AEs in patients, 4 investigative studies were performed in a step-wise approach to assess retinal structure and function in pigmented (Brown Norway) and albino (Wistar) rats. In rats administered 30mg/kg of AUY922, the AUC 0-24 h and Cmax are comparable to that in patients at 70mg/m(2). AUY922 at ≥30mg/kg was poorly tolerated by rats with morbidity or mortality generally after the third weekly treatment. Electroretinography (ERG) changes were observed at doses ≥30mg/kg. The ERG changes were dose dependent, consistent with an effect on the photoreceptors, and fully reversible. The ERG effects could not be minimized by decreasing the Cmax while maintaining AUC. Histopathological changes were seen mainly when rats were administered AUY922 at 100mg/kg. The 2- hour infusion of AUY922 at 100mg/kg caused disorganization of the outer segment photoreceptor morphology in male Brown Norway rats; the severity of the disorganization increased with the number of administrations, but was reversible during a 4- week posttreatment period. There was no major difference in ocular response between Brown Norway and Wistar rats. No changes in serum iron levels, and no changes in rhodopsin, PDE6α, β-transducin concentrations, or retinal pigment epithelium-specific protein RPE65 expression were observed after single and multiple infusions of AUY922 at 100mg/kg compared to vehicle-treated controls. AUY922 retinal toxicity in rats recapitulates and further characterizes that reported in patients and is shown to be reversible, while a precise molecular mechanism for the effect was not determined.
27576608	0	15	Ocular toxicity	T037	C1262036
27576608	19	25	AUY922	T109,T121	C2348996
27576608	29	38	pigmented	T015	C0034700
27576608	43	54	albino rats	T015	C0684072
27576608	55	61	AUY922	T109,T121	C2348996
27576608	65	86	heat shock protein 90	T116,T123	C0243044
27576608	87	96	inhibitor	T080	C1999216
27576608	116	122	ocular	T023	C0015392
27576608	123	137	adverse events	T046	C0877248
27576608	139	142	AEs	T046	C0877248
27576608	182	188	ocular	T023	C0015392
27576608	189	192	AEs	T046	C0877248
27576608	196	204	patients	T101	C0030705
27576608	208	229	investigative studies	T062	C2603343
27576608	250	268	step-wise approach	T082	C0449445
27576608	279	296	retinal structure	T023	C0035298
27576608	313	322	pigmented	T015	C0034700
27576608	324	336	Brown Norway	T015	C0034700
27576608	342	362	albino (Wistar) rats	T015	C0684072
27576608	350	356	Wistar	T015	C0034716
27576608	367	371	rats	T015	C0034721
27576608	372	384	administered	T169	C1521801
27576608	396	402	AUY922	T109,T121	C2348996
27576608	408	411	AUC	T081	C0376690
27576608	417	418	h	T079	C0439227
27576608	423	427	Cmax	T081	C2347813
27576608	454	462	patients	T101	C0030705
27576608	477	483	AUY922	T109,T121	C2348996
27576608	520	524	rats	T015	C0034721
27576608	530	539	morbidity	T081	C0026538
27576608	543	552	mortality	T081	C0596099
27576608	579	585	weekly	T079	C0332174
27576608	586	595	treatment	T061	C0087111
27576608	597	616	Electroretinography	T060	C0013867
27576608	618	621	ERG	T060	C0013867
27576608	623	630	changes	T169	C0392747
27576608	648	653	doses	T081	C0178602
27576608	668	671	ERG	T060	C0013867
27576608	672	679	changes	T169	C0392747
27576608	685	699	dose dependent	T081	C1512045
27576608	701	711	consistent	T078	C0332290
27576608	734	748	photoreceptors	T025	C0031760
27576608	760	770	reversible	T169	C0205343
27576608	776	779	ERG	T060	C0013867
27576608	829	833	Cmax	T081	C2347813
27576608	852	855	AUC	T081	C0376690
27576608	857	874	Histopathological	T169	C0243140
27576608	875	882	changes	T169	C0392747
27576608	905	909	rats	T015	C0034721
27576608	915	927	administered	T169	C1521801
27576608	928	934	AUY922	T109,T121	C2348996
27576608	955	959	hour	T079	C0439227
27576608	960	968	infusion	T061	C0574032
27576608	972	978	AUY922	T109,T121	C2348996
27576608	998	1013	disorganization	T033	C4061689
27576608	1021	1048	outer segment photoreceptor	T026	C1325525
27576608	1049	1059	morphology	T080	C0332437
27576608	1063	1067	male	T032	C0086582
27576608	1068	1085	Brown Norway rats	T015	C0034700
27576608	1107	1122	disorganization	T033	C4061689
27576608	1152	1167	administrations	T061	C1533734
27576608	1177	1187	reversible	T169	C0205343
27576608	1200	1204	week	T079	C0439230
27576608	1205	1225	posttreatment period	T079	C2709088
27576608	1260	1266	ocular	T023	C0015392
27576608	1267	1275	response	T032	C0871261
27576608	1284	1296	Brown Norway	T015	C0034700
27576608	1301	1312	Wistar rats	T015	C0034716
27576608	1328	1345	serum iron levels	T034	C0036810
27576608	1365	1374	rhodopsin	T116,T123	C0035499
27576608	1376	1381	PDE6α	T116,T126	C1567350
27576608	1383	1395	β-transducin	T116,T123	C0040665
27576608	1396	1410	concentrations	T081	C0392762
27576608	1415	1464	retinal pigment epithelium-specific protein RPE65	T116,T123	C1571376
27576608	1465	1475	expression	T045	C0017262
27576608	1516	1525	infusions	T061	C0574032
27576608	1529	1535	AUY922	T109,T121	C2348996
27576608	1560	1584	vehicle-treated controls	T096	C0009932
27576608	1586	1592	AUY922	T109,T121	C2348996
27576608	1593	1609	retinal toxicity	T190	C0877104
27576608	1613	1617	rats	T015	C0034721
27576608	1675	1683	patients	T101	C0030705
27576608	1703	1713	reversible	T169	C0205343
27576608	1731	1750	molecular mechanism	T044	C1258062